27
Evidence for Use of Risk
Assessment Factors/Tools
Evidence for Use of PAH-Specific
Therapy
Patient age, pretricuspid shunt, resting
oxygen saturation, loss of sinus rhythm,
pericardial effusion, BNP, C-reactive
protein, 6MWD, echocardiography,
renal dysfunction, or other clinical
stratification tools.*
Endothelin-receptor antagonists,
phosphodiesterase-5 inhibitors, prostacylin
analogs
†
Review using the 3-strata risk-prediction
model for newly diagnosed patients,
the 4-strata risk-prediction model for
patients with established PAH, and/or
any of the Eisenmenger syndrome tools.
‡
No direct studies on this isolated
cohort; treatment has typically followed
recommendations for idiopathic PAH
Review using the 3-strata risk-prediction
model for newly diagnosed patients,
the 4-strata risk-prediction model for
patients with established PAH, and/or
any of the Eisenmenger syndrome tools.
‡
No direct studies on this isolated
cohort; treatment has typically followed
recommendations for idiopathic PAH
Review using the 3-strata risk-prediction
model for newly diagnosed patients,
the 4-strata risk-prediction model for
patients with established PAH, and/or
any of the Eisenmenger syndrome tools.
‡
Phosphodiesterase-5 inhibitors, endothelin
receptor antagonists, oral prostacyclin
receptor analog, activin signaling inhibitors
§
